Zentalis Pharmaceuticals/$ZNTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Ticker
$ZNTL
Sector
Primary listing
Employees
106
Headquarters
Website
ZNTL Metrics
BasicAdvanced
$310m
-
-$1.74
1.98
-
Price and volume
Market cap
$310m
Beta
1.98
52-week high
$6.95
52-week low
$1.15
Average daily volume
1.2m
Financial strength
Current ratio
6.19
Quick ratio
6.01
Long term debt to equity
18.968
Total debt to equity
21.158
Profitability
EBITDA (TTM)
-141.476
Effective tax rate (TTM)
-0.45%
Management effectiveness
Return on assets (TTM)
-27.88%
Return on equity (TTM)
-51.93%
Valuation
Price to book
1.7
Price to tangible book (TTM)
1.7
Price to free cash flow (TTM)
-2.48
Free cash flow yield (TTM)
-40.33%
Free cash flow per share (TTM)
-1.756
Growth
Earnings per share change (TTM)
-44.82%
3-year earnings per share growth (CAGR)
-25.97%
What the Analysts think about ZNTL
Analyst ratings (Buy, Hold, Sell) for Zentalis Pharmaceuticals stock.
ZNTL Financial Performance
Revenues and expenses
ZNTL Earnings Performance
Company profitability
ZNTL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs